Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - INTERCEPT PHARMACEUTICALS, INC. | v456571_exhx32.htm |
| EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC. | v456571_exh31x2.htm |
| EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC. | v456571_exhx31x1.htm |
| EX-21.1 - EXHIBIT 21.1 - INTERCEPT PHARMACEUTICALS, INC. | v456571_exhx21x1.htm |
| EX-12.1 - EXHIBIT 12.1 - INTERCEPT PHARMACEUTICALS, INC. | v456571_ex12-1.htm |
| EX-10.18 - EXHIBIT 10.18 - INTERCEPT PHARMACEUTICALS, INC. | v456571_ex10-18.htm |
| EX-10.17 - EXHIBIT 10.17 - INTERCEPT PHARMACEUTICALS, INC. | v456571_ex10-17.htm |
| EX-10.11 - EXHIBIT 10.11 - INTERCEPT PHARMACEUTICALS, INC. | v456571_ex10-11.htm |
| 10-K - 10-K - INTERCEPT PHARMACEUTICALS, INC. | v456571_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Intercept Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-184810, No. 333-188064, and No. 333-206247) and Form S-3 (No. 333-194974) of our report dated March 1, 2017 with respect to the consolidated balance sheets of Intercept Pharmaceuticals, Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and the effectiveness of internal control over financial reporting as of December 31, 2016, which reports appear in the December 31, 2016 annual report on Form 10-K of Intercept Pharmaceuticals, Inc.
/s/ KPMG LLP
New York, New York
March 1, 2017